amethyst radiotherapy

Amethyst Radiotherapy Featured On E-Klinika Platform

/in

Serbian medical platform e-Klinika has just featured an interview with Dr Paul Stuchetz, the director of the Amethyst Radiotherapy Centre, a leading private practice based in Vienna, Austria, and which specialises in the provision of oncology radiotherapy services.

About the Amethyst Group

The Amethyst Group was first established some 15 years ago and has gone on to launch 16 centres in six different European countries: the UK, Romania, Poland, Italy, France and Austria. It treats more than 40,000 cancer patients annually, using radiotherapy to tackle various different forms of the disease.

A Unique Approach to Patient Care

Speaking to the news source, Dr Stuchetz explained that the facility embraces an interdisciplinary approach to healthcare, which is why it stands out as a centre of excellence in the field of radiation oncology, coupled with its commitment to innovation and quality in diagnostics and treatment, as well as prioritising patient wellbeing and comfort.

Safe and Structured Care for International Patients

Providing healthcare for patients from abroad involves following a precisely defined and structured procedure to ensure full regulatory compliance and medical safety, as well as a safe and efficient patient experience.

A team of medical experts come together to look at each individual case, including oncologists, physicists, radiation therapists and surgeons. Integrative therapies and psychological support are also available, with the goal being to make patients feel good both during and after treatment, supporting their general quality of life.

Dr Stuchetz said: “I think the most important message is that patients can give us their trust. We have an individual approach to each patient, which is what we are particularly oriented towards. Also, at Amethyst, they will be in safe hands, because only highly qualified doctors and specialists who have access to the latest medical achievements work with us.”

 

Support for Serbian Patients

For Serbian patients interested in finding out more about how the centre could help them throughout their cancer journey, Dr Stuchetz advised them to get in touch with associate Maja Zakarija (+381 63 388 546), who will be able to provide them with all the necessary support in their native language.

 

Learn more about our advanced radiotherapy and neurosurgical treatments for different cancers on the Amethyst Group website.

Amethyst Radiotherapy Austrai David on Precision Tumour Care

Inside Amethyst Austria: Innovation and Compassion in Cancer Care

/in

As part of the Amethyst Healthcare Group, Amethyst Radiotherapy Austria plays a vital role in delivering personalised, non-invasive cancer care across Central Europe. Based within Vienna’s prestigious Wiener Privatklinik (WPK), the centre reflects our Group-wide values: clinical precision, compassionate delivery, and accessible pathways to care.

 

To mark WPK’s 30th anniversary, Dr David, Clinical Lead at Amethyst Austria, joined the celebrations to share insights into how the centre is advancing modern cancer treatment. In this special interview, he reflects on our mission and how we leverage advanced radiosurgery to support patient wellbeing.

 

▶ Watch Dr David share our clinical approach and patient philosophy below.

 

What Sets Amethyst Austria Apart

Amethyst Austria specialises in stereotactic radiosurgery (SRS)—a technique that uses highly focused radiation to treat tumours with millimetre-level accuracy. This non-invasive alternative to surgery eliminates the need for incisions, hospital stays, or extended recovery time.

In the interview, Dr David highlights four pillars that underpin our clinical approach:

  • Pinpoint Accuracy
    We use high-resolution imaging technologies—including MRI, CT, and PET scans—to localise tumours with exceptional precision.
  • Non-Invasive Delivery
    Using the Elekta Versa HD linear accelerator, we deliver targeted radiation directly to the tumour site without affecting surrounding healthy tissue.
  • Rapid Access
    Patients benefit from minimal waiting times, with same-day consultations and streamlined treatment planning.
  • Tailored Pathways
    Each patient receives an individualised treatment plan, aligned with their specific diagnosis and health needs.

 

A Group-Wide Commitment to Excellence in Care

Across all Amethyst centres, our core mission remains the same: to provide timely, evidence-based, and compassionate cancer care using the most effective radiotherapy techniques available.

Amethyst Austria brings this philosophy to life by offering precise, non-invasive treatments in a calm, supportive, and professional setting. The centre exemplifies our belief that advanced technology should always be paired with genuine human care.

By continuously refining our techniques and embracing innovation, we help patients regain control, maintain quality of life, and move forward with confidence.

Amethyst CEO Discusses New Partnership And Future Plans

/in

Amethyst Healthcare CEO, Stéphane Carré, has spoken to Healthcare Business International about the company’s new partnership with Fremman Capital, a European private equity firm. 

Amethyst were founded in Romania 15 years ago, and have since expanded throughout Europe to provide private radiation therapy, chemotherapy, brachytherapy, and supportive therapies to cancer and brain tumour patients. 

Carré discusses the future direction that Amethyst will take, including a more holistic approach to cover every stage of the care pathway, and also the future investment and expansion plans. Here’s a look at the main points of his interview.

The Fremman Capital partnership

Carré explains that the deal with Fremman Capital was agreed after almost 12 months of negotiations. 

He commented: “From our first conversations with Fremman in June last year, it was clear we were closely aligned, both in Amethyst’s growth potential and the strategic direction we’ve taken since I joined. Fremman quickly stood out as the right partner in terms of scale, strategic alignment, and operational support.”

The future direction of Amethyst

Expanding Access to Cancer Care Across and Beyond Europe

Carré made it clear that Amethyst is keen to expand the therapies and services it offers, as well as establish new treatment centres in Europe. Currently, the company operates 17 centres across six European countries, and treats over 50,000 patients each year. In countries such as the UK and France, it collaborates with public healthcare providers. 

Germany is seen as a priority country to expand to, and Europe will remain the centre of their operations. However, Carré explained that the company will continue to work to widen access to patients from outside Europe, particularly those from areas of the world that are currently underserved by radiation therapy services, such as parts of Africa and the Gulf. 

Prioritising patient-centred care

Amethyst is planning to widen its focus to include pre and post-treatment services, such as counselling and nutritional support. Another key strategy is expanding provisions into chemotherapy and diagnostic services. Such a joined-up approach can speed up treatment times and provide a more transparent and reassuring experience for patients. 

Carré commented: “Our aim is to support patients from the earliest stage of diagnosis right through to the end of treatment. And even beyond that we offer post-treatment services such as psychological counselling and generic advice, both of which are crucial to patient wellbeing.”

The role of technology and AI in future treatments

Amethyst is committed to investing in cutting-edge technologies that will keep the company at the forefront of cancer and brain tumour treatment. These include using AI and digital tools to create more personalised treatment plans and improve digital efficiencies. 

Carré explains: “AI enables us to tailor treatment plans to each individual — each tumour, each case. We’re already using AI during treatment planning and the contouring phase. As you may know, radiotherapy consists of three main stages: planning, tumour contouring, and treatment delivery.”

The Amethyst patient app

The Amethyst patient app is currently in development, and it will allow patients to take ownership of their care journey and help them to understand their specific condition in a clear and user-friendly way. Ultimately, this will build a ‘one point of contact’ model and deliver a more unified and accessible patient experience. 

AI to support image analysis

Tumour contouring, the process of analysing MRI scans to precisely map the location, size and shape of a tumour, is a very time intensive process and can be subject to human error and the vagaries of human interpretation. This can be particularly the case for brain tumours that do not have well defined boundaries, or multiple small tumours are present.

AI automation has shown to provide more consistent results, reducing instances of variabilities and oversights. This allows for a more time efficient approach, and a more precise delivery of radiation to the tumour cells, reducing the risk of complications and side effects. 

The use of AI tools is also being explored for delivering the effective and accurate radiation dose to the tumour cells, minimising the risk of damage to the surrounding tissues. Furthermore, research is ongoing into treating conditions beyond tumours, such as Parkinson’s disease and certain psychiatric disorders. 

Public-Private Partnerships

Carré emphasised the importance of consolidation in the radiotherapy market, as well as the company’s intention to strengthen public-private partnerships (PPPs) in its future healthcare strategy. 

He points out that high-quality cancer care requires significant investment, and as public healthcare budgets are currently under strain with little sign of improvement, he regards PPPs as essential to meet future demand. This is why PPPs will remain an important element of Amethyst’s growth strategy.

Carré comments: “We help public facilities increase their treatment capacity, modernise equipment, and improve access. In countries like France, if a public hospital can’t treat a minimum number of patients annually, it risks losing its licence. By operating on their behalf, we help them maintain accreditation, treat more patients, and enhance care.”

“It’s an innovative model that’s still underutilised in Europe and we’re committed to playing a leading role in its development.”

The future of cancer care

As we are faced with an ageing population, an increase in unhealthy lifestyle habits, and improved diagnostics leading to more cancer patients at an earlier age, the demand for world-class cancer care services is highly likely to increase in the future. 

Amethyst Radiation Oncology Expert Featured On Zena Platform

/in

Dr David Kuczer, radiation oncology expert with Amethyst Group, has been interviewed by leading Serbian news platform Zena, talking about the role that radiotherapy has to play in breast cancer treatments.

Speaking to the news source, Dr Kuczer explained that all treatments are individually designed to suit each specific patient, using the most innovative and up-to-date knowledge to deliver optimal results, medically and aesthetically.

The interdisciplinary team at Amethyst’s Department of Tumours works collaboratively to come up with uniquely tailored approaches to patient care. From Dr Kuczer’s perspective, he believes it’s most important to spend time with patients while working on idea exchanges with colleagues and finding the best treatment options on a case by case basis.

He said: “Thanks to modern technology, the therapy has been reduced from about 30 treatments during six weeks to five to 20 treatments over the course of one to four weeks, depending on the individual case. The sessions last ten minutes and are performed on an outpatient basis.”

Around 50 per cent of all breast cancer patients will have to have radiotherapy, with high doses of radiation directed towards tumours to damage diseased cell DNA sufficiently to prevent multiplication. Once the tumour cells die, they’re broken down by the body.

This way of working means that tissue affected by the tumour can be removed, protecting the entirety of the breast and removing the need for complete removal. Recurrence is also prevented through the elimination of microscopic tumour remnants.

Finding innovative ways of treating cancer is a must, given that the disease is the leading cause of death around the world, with nearly ten million fatalities each year.

Here at Amethyst Group, we work tirelessly to identify new treatment methods to kill and eliminate malignant cells while preserving healthy tissue. To find out more, get in touch with the team today.

Serbian News Portal Features Amethyst Austria

/in

BLIC, one of the leading news portals in Serbia, has just published an article on its platform showcasing cancer care provider Amethyst Austria and its successes in fighting cancer using innovative radiotherapy treatments and techniques.

The article features Dr Alinca Sturdza, radiation oncology expert and gynecology expert, who trained in her specialism at Princess Margaret University Hospital in Toronto.

Dr Sturdza said: “As an expert in brachytherapy, one of the most precise forms of cancer treatment with radiation, I use the most modern methods of radiotherapy. Thanks to the constant advances in oncology, cancer is becoming a chronic disease in many cases and I’m here to support patients on that journey as best as possible.”

The radiotherapy centre itself can be found in the heart of Vienna, enjoying close relationships with a team of international cancer experts to help people from all over the world receive the highest standards of care possible through the provision of the most advanced form of cancer therapy.

Also featured in the BLIC news piece was radiation oncology specialist Dr David Kuczer, who has over 20 years of experience in radiation therapy, treating cancerous lesions including breast and prostate cancer.

At the Austria clinic, radiotherapy techniques have been developed to make sure that optimal radiation doses are targeted towards tumours, ensuring that minimal damage is done to surrounding health tissue.

Over the years, we have built up an established network of clinics and work closely with experienced partners to deliver highly coordinated specialist teams for cancer treatment. As such, patients can expect to receive expert care and optimal treatment, inline with international and national guidelines.

To find out more about the different therapy options available and how they could help support you in your cancer journey, get in touch with the Amethyst Austria team today.

Amethyst Healthcare Acquired by Fremman

Amethyst Healthcare Group Enters Growth Chapter with Acquisition by Fremman Capital

/in ,

Amethyst Radiotherapy Group (“Amethyst”), a leading pan-European provider of cancer care services, today announced that it has entered into an agreement to be acquired by Fremman Capital, a pan-European mid-market private equity firm. This strategic partnership marks a significant milestone in Amethyst’s journey and sets the stage for accelerated expansion and innovation across the European oncology landscape.

Founded in 2010, Amethyst has become one of the largest independent radiotherapy providers in Europe. Operating 19 cutting-edge cancer treatment centers across France, Poland, Romania, the UK, Italy, and Austria, Amethyst treats more than 50,000 patients annually. The Group delivers a comprehensive suite of oncology services — primarily radiotherapy — through a dedicated team of over 500 healthcare professionals and in collaboration with nearly 100 partner physicians.

As part of the transaction, Fremman Capital will acquire a majority stake in Amethyst, while the company’s founding shareholders and The Rohatyn Group will fully exit their investment. Fremman brings deep experience in healthcare and a strong track record of scaling essential service providers across Europe, making them a natural partner to support Amethyst’s long-term vision.

This partnership with Fremman marks a new era of opportunity for Amethyst,” said Stéphane Carré, CEO of Amethyst Radiotherapy Group.

“Their expertise in healthcare and long-term investment philosophy aligns perfectly with our mission: to deliver advanced, accessible cancer care to more people, in more places. With their support, we will continue investing in cutting-edge technologies, expanding our footprint both organically and through partnerships and M&A, making a difference in the lives of patients and families across Europe.”

 

Amethyst has built a strong reputation for clinical excellence, operating nearly 40 state-of-the-art linear accelerators — the primary technology used in modern radiotherapy — and forming long-standing partnerships with public health systems to ensure the equitable delivery of life-saving care.

The radiotherapy market continues to show strong growth, driven by rising cancer incidence and increasing recognition of radiotherapy as a highly effective, non-invasive treatment option with minimal side effects. Fremman’s investment underscores the strength of Amethyst’s model and its leadership position in this critical area of cancer care.

The transaction is expected to close in the coming months, subject to customary regulatory approvals.

 

About Amethyst Radiotherapy
Amethyst is a leading European cancer care provider specialising in radiotherapy, chemotherapy, and diagnostic imaging. With operations in six countries and 19 centers, Amethyst combines clinical excellence with patient-centered care to improve access to oncology treatment across Europe. The Group partners closely with public healthcare systems, delivering services under reimbursement-based models.

About Fremman

Fremman Capital is a pan-European, mid-market investment firm with offices in London, Luxembourg, Paris, Madrid, and Munich. The firm partners with ambitious management teams to help transform businesses into multinational sustainable leaders, particularly in sectors essential to society such as healthcare, technology, and business services.

For more information: www.fremman.com

Media Contact:
Sophie Ward
Email Address: [email protected]
Phone Number: +44 208 713 0460
Organisation Website: www.amethysthealthcare.com

Inside Amethyst Healthcare’s PPP Strategy with CEO Stephane Carre

/in , ,

In today’s rapidly evolving healthcare landscape, Public–Private Partnerships (PPPs) represent more than just a financial model—they serve as a cornerstone for innovation, increased access, and long-term sustainability. Amethyst Healthcare Group, under the leadership of CEO Stéphane Carré, is championing this approach. In a recent interview with The CEO Magazine, Carré detailed how Amethyst is strategically leveraging PPPs to deliver cutting-edge cancer care to more patients across Europe.

The Role of PPPs in Modern Healthcare

Healthcare systems across Europe are grappling with a dual pressure: tightening budgets and rising demand for services. PPPs present a viable solution by combining the reach and reliability of public institutions with the agility and technological edge of private enterprise. When executed effectively, these partnerships can enhance service quality, increase efficiency, and broaden patient access.

Amethyst has been a firm advocate of this collaborative model since its inception. Through enduring partnerships with hospitals and public health organizations, the company provides advanced radiotherapy services—relieving pressure on public resources while ensuring high standards of patient care. This alignment results in a dual benefit: enhanced healthcare delivery for patients and sustainable models for providers.

Expanding Access Through Real-World Impact

One notable example of Amethyst’s PPP success is its collaboration with Centre Hospitalier de Troyes in France. By managing the hospital’s radiotherapy unit, Amethyst enables the facility to offer cutting-edge treatments without requiring a substantial capital outlay. This approach removes financial and operational barriers, significantly improving access to lifesaving care—especially in underserved regions.

In the UK, the company’s acquisition of Queen Square Radiosurgery Centre in London brought advanced Gamma Knife technology to both private and NHS patients. Since 2023, patient numbers at the center have doubled, underscoring how PPPs can rapidly enhance treatment capacity and introduce breakthrough technologies into public healthcare frameworks.

Driving Innovation While Sharing Risk

One of the key advantages of PPPs is the ability to introduce innovation without placing the entire financial or operational burden on public systems. Amethyst’s model epitomizes this principle. By investing in and managing radiotherapy centers on behalf of public institutions, the Group delivers excellence in care with a streamlined, patient-focused approach.

This model not only facilitates faster adoption of advanced technology but also enhances overall service quality—reducing waiting times, minimizing inefficiencies, and improving patient outcomes.

Scaling for Sustainable Impact

Since 2020, Amethyst has recorded an 84% increase in the number of patients treated annually, including a 70.1% rise in NHS-referred patients. These figures highlight more than just growth—they reflect the potential of PPPs to sustainably expand healthcare capacity and ease the burden on national systems like the NHS.

Looking ahead, Amethyst plans to scale its operations to 50 clinics and over 100 linear accelerators across Europe. This ambitious expansion is firmly anchored in its PPP-driven strategy, which remains a central pillar of the Group’s vision for the future.

Redefining Collaborative Healthcare

For Amethyst, PPPs are not merely funding mechanisms—they are strategic enablers. By aligning the capabilities of the private sector with the needs of the public, these partnerships create resilient systems that can grow, adapt, and consistently deliver high-quality care.

As Stéphane Carré noted in his interview with The CEO Magazine, the future of healthcare lies in intelligent collaboration. PPPs will continue to play a transformative role—not just in oncology, but across all sectors of healthcare seeking scalable, impactful, and sustainable solutions. Amethyst Healthcare is proud to be leading this transformation.

Read the full interview with Stéphane Carré in The CEO Magazine for more insights into Amethyst Healthcare Group’s inspiring journey.
Radiotherapy Treatment - MRI Scan

What’s Next For Gamma Knife Radiosurgery & AI Technology?

/in , ,

One of the most effective and advanced treatment resources for brain tumours and vascular malformations is Gamma Knife radiosurgery, which first came to the fore during the 1960s and which has continued to evolve quickly ever since.

With the advent of artificial intelligence (AI) over the last year or so, new and exciting opportunities are starting to emerge… some of which have just been published in the spring edition of SCOPE magazine, with contributions from our own clinical team, including Ian Paddick (consultant physicist at Queen Square) and Hannah Bouas (radiosurgery physicist at Thornbury Radiosurgery Centre).

The focus here is on AI-driven auto-contouring for tumour segmentation, achieving greater levels of precision and more consistent patient outcomes in stereotactic radiosurgery.

Read on to find out more about the key conclusions drawn in the Scope piece.

AI-driven auto-contouring for advanced precision

AI-driven auto-contouring for tumour segmentation is a significant breakthrough in Gamma Knife technology, moving away from manual processes that are time consuming and subject to risks posed by human interpretation, particularly in lesions and tumours that don’t have clearly defined boundaries.

Using AI frameworks allow clinicians to segment tumour boundaries with the equivalent accuracy to human annotators, the advantages of which include:

– Reduced human error: Consistency is achieved through AI automation, lowering the risk of inaccurate results while reducing variability and oversights significantly.

– Enhanced patient outcomes: AI tools ensure greater accuracy of tumour segmentation, resulting in more precise radiation delivery to tumour cells and reducing damage risks to healthy brain tissue, as well as reducing the risks of complications and side-effects.

– Efficiency gains: Automation allows for more efficient contour detection in much shorter timescales, thus allowing for faster overall treatment times and reduced waiting lists.

Potential limitations of AI

Although the Scope article does note that AI is an incredibly valuable tool, models for auto-contouring still have some limitations, such as incomplete training data that may not generalise across diverse populations, or imaging noise that results in false positives.

While AI will undoubtedly become more important as a resource in the future, for now clinical oversight and judgement of contouring processes will still be necessary, particularly for more complex cases such as brain metastases.

Amethyst France Partners with CROMG to Improve Cancer Care

/in

Amethyst Radiotherapy France is proud to announce a strategic partnership with the Centre Radiothérapie Oncologie Moyenne Garonne (CROMG), a renowned radiotherapy centre based in Agen. This new collaboration marks a significant step forward in advancing oncology care in the South of France, uniting two organisations committed to delivering exceptional radiotherapy services through innovation, expertise, and compassion.

Founded in 2008, CROMG has long been recognised as a leader in the region, equipped with three state-of-the-art linear accelerators (Linacs) and a highly experienced medical team. Through this partnership, Amethyst aims to reinforce CROMG’s legacy while introducing enhanced clinical pathways, advanced technologies, and broader access to patient-centric treatment closer to home.

“This partnership reflects our shared vision to provide world-class radiotherapy services and ensure patients across the Nouvelle-Aquitaine region have access to the latest in cancer treatment,” said Olivier Cosset, Amethyst France CEO. “We are excited to welcome the CROMG team into the Amethyst family and support the continued growth of their outstanding medical expertise.”

By integrating resources, teams, and know-how, Amethyst and CROMG will work together to maintain the highest standards of care while expanding access and strengthening local oncology networks. The partnership will also foster the development of multidisciplinary approaches, supporting not only radiotherapy but broader oncology collaboration across the region.

This collaboration marks an exciting milestone in Amethyst’s continued expansion in France, reinforcing its mission to make high-quality, innovative radiotherapy accessible to more patients, wherever they are.

About Amethyst Radiotherapy
Amethyst Radiotherapy is one of Europe’s leading private cancer treatment providers, delivering high-precision radiotherapy services through a network of state-of-the-art centres. With a strong presence in France and across Europe, Amethyst is dedicated to innovation, medical excellence, and improving patient outcomes.

About CROMG
The Centre Radiothérapie Oncologie Moyenne Garonne (CROMG) has been at the heart of cancer care in Agen since 2008. Committed to personalised treatment and cutting-edge radiotherapy, the centre is home to an expert medical team, serving patients across the Nouvelle-Aquitaine region with compassion and excellence.

Media Contact:
Sophie Ward
Email Address: [email protected]
Phone Number: +44 208 713 0460
Organisation Website: www.amethysthealthcare.com

Amethyst Radiotherapy France To Appear On Check-Up Santé

/in , ,

Acclaimed French television show Check-Up Santé on BFM TV , which focuses on health information and regularly invites medical experts onto the stage to discuss important topics of the day, has asked Olivier Cosset, CEO of Amethyst Radiothérapie France, to appear as a guest on Saturday, 22nd February and Sunday 23rd February.

Mr Cossett will be on the BFM TV flagship health programme talking in depth about the latest innovations in radiotherapy and the increasingly important role the practice has to play in modern cancer treatment, delivering insights into how it is evolving to make cancer treatment more effective and accessible.

“Radiotherapy is undergoing a true revolution, with advancements that are making treatments more precise, efficient, and accessible to more patients than ever before. At Amethyst Radiothérapie France, we are committed to bringing the latest innovations in radiotherapy to improve patient care and outcomes. I look forward to discussing these exciting developments on Check-Up Santé with Fabien Guez and shedding light on how radiotherapy is shaping the future of cancer treatment.”

– Olivier Cosset, CEO of Amethyst Radiothérapie France

Amethyst Radiothépie is one of the biggest private providers of radiotherapy services in France, providing cutting-edge treatments to enhance the patient journey and improve health outcomes across the board.

The episode is due to air on 22nd February at 14:00 EST and Sunday 23rd February at 15:00 EST on BFM TV. Make sure you tune in to hear a truly fascinating discussion on radiotherapy innovation and what the future of cancer care will look like.

Also featuring on the show will be Professor Jean-Emmanuel Bibault, who will be talking about the long history of cancer (which dates all the way back to prehistoric times), just one of the points raised in his book Cancer Confidential: L’histoire du cancer, des secrets d’hier aux revolutions de demain.